Connect
MJA
MJA

The value of novel oral anticoagulants in rural Australia

Ke Xu, Noel C Chan and John W Eikelboom
Med J Aust 2018; 208 (1): 15-16. || doi: 10.5694/mja17.00592
Published online: 15 January 2018

The new agents offer important safety and convenience advantages, but need to win the confidence of clinicians and patients

For more than 60 years, vitamin K antagonists, such as warfarin, have been the only option for long term oral anticoagulation therapy. Although effective for preventing and treating thromboembolism, warfarin is underused because controlling coagulation time (as measured by the international normalised ratio [INR]) is complex, and because of concerns about the risk of bleeding.1 Even when warfarin therapy is carefully managed, the INR of some patients is frequently outside the target range. Poor warfarin therapy control is associated with an increased risk of thromboembolism and bleeding. More convenient and safer oral anticoagulants are urgently needed.2

  • Ke Xu1
  • Noel C Chan2,3
  • John W Eikelboom1,2,3

  • 1 Population Health Research Institute, Hamilton, ON, Canada
  • 2 Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
  • 3 McMaster Clinic, Hamilton, ON, Canada

Correspondence: eikelbj@mcmaster.ca

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.